Pharmaceutics (Dec 2022)

Aptamers Enhance Oncolytic Viruses’ Antitumor Efficacy

  • Maya A. Dymova,
  • Anna S. Kichkailo,
  • Elena V. Kuligina,
  • Vladimir A. Richter

DOI
https://doi.org/10.3390/pharmaceutics15010151
Journal volume & issue
Vol. 15, no. 1
p. 151

Abstract

Read online

Oncolytic viruses are highly promising for cancer treatment because they target and lyse tumor cells. These genetically engineered vectors introduce therapeutic or immunostimulatory genes into the tumor. However, viral therapy is not always safe and effective. Several problems are related to oncolytic viruses’ targeted delivery to the tumor and immune system neutralization in the bloodstream. Cryoprotection and preventing viral particles from aggregating during storage are other critical issues. Aptamers, short RNA, or DNA oligonucleotides may help to crawl through this bottleneck. They are not immunogenic, are easily synthesized, can be chemically modified, and are not very demanding in storage conditions. It is possible to select an aptamer that specifically binds to any target cell, oncolytic virus, or molecule using the SELEX technology. This review comprehensively highlights the most important research and methodological approaches related to oncolytic viruses and nucleic acid aptamers. Here, we also analyze possible future research directions for combining these two methodologies to improve the effectiveness of cancer virotherapy.

Keywords